Informed Consent for Assisted Reproduction:

**In Vitro Fertilization,**
**Intracytoplasmic Sperm Injection**
** Assisted Hatching**
**Embryo Freezing**

Dartmouth-Hitchcock Medical Center (DHMC)

OVERVIEW

In Vitro Fertilization (IVF) has become an established treatment for many forms of infertility. The main goal of IVF is to allow a patient the opportunity to become pregnant using her own or donated eggs and sperm from her partner or from a donor. This is an elective procedure designed to result in the patient’s pregnancy when other treatments have failed or are not appropriate.

This consent reviews the IVF process from start to finish, including the risks that this treatment might pose to you and your offspring. While best efforts have been made to disclose all known risks, there may be risks of IVF which are not yet clarified or even suspected at the time of this writing.

An IVF cycle typically includes the following steps or procedures:

- Medications to grow multiple eggs
- Retrieval of eggs from the ovary or ovaries
- Insemination of eggs with sperm
- Culture of any resulting fertilized eggs (embryos)
- Placement (“transfer”) of one or more embryo(s) into the uterus
- Support of the uterine lining with hormones to permit and sustain pregnancy

In certain cases, these additional procedures can be employed:

- Intracytoplasmic sperm injection (ICSI) to increase the chance for fertilization
- Assisted hatching of embryos to increase the chance of embryo attachment (“implantation”)
- Embryo freezing (Cryopreservation)

Note: At various points in this document, rates are given which reflect what are believed to be U.S. national averages for those employing IVF treatments. These include items such as pregnancy rates, Cesarean delivery rates, and preterm delivery rates. These rates are not meant to indicate the rates of these outcomes within individual practices offering IVF and are not to be understood as such. Individual practices may have higher or lower pregnancy and delivery rates than these national rates.

Initials: Patient __________________      Partner (if applicable) __________________
It is appropriate to ask DHMC about our specific rates.

Also note that while this information is believed to be up to date at the time of publication (see Version Date below), newer reports may not yet be incorporated into this document.

Outline of Consent for Assisted Reproductive Technology (ART)

A. Technique of In Vitro Fertilization
   1. Core elements and their risk
      a. medications
      b. oocyte retrieval
      c. in vitro fertilization and embryo culture
      d. embryo transfer
      e. hormonal support of the uterine lining
   2. Additional elements and their risk
      a. Intracytoplasmic sperm injection (ICSI)
      b. assisted hatching
      c. embryo freezing
      d. embryo disposition storage exceptions

B. Risks to the woman
   1. ovarian hyperstimulation syndrome
   2. oocyte retrieval
   3. risks of pregnancy

C. Risks to offspring
   1. overall risks
   2. birth defects
   3. risks of multiple pregnancy

D. Ethical and religious considerations in infertility treatment

E. Psychosocial effects of infertility treatment

F. Legal considerations and legal counsel

G. Alternatives to IVF

H. Reporting outcomes
I. Donated gametes

J. Additional understandings and signatures

A. Technique of IVF

1. Core elements and their risk

a. Medications for IVF Treatment

- **Gonadotropins, or injectable “fertility drugs”**: These hormones stimulate the ovary in hopes of inducing the simultaneous growth of several oocytes (eggs) over the span of 7 or more days. Injectable fertility drugs have FSH (follicle stimulating hormone), a hormone that will stimulate the growth of your ovarian follicles (which contain the eggs). Some of them also contain LH (luteinizing hormone). LH is a hormone that may work with FSH to increase the production of estrogen and growth of the follicles. These medications are given by subcutaneous or intramuscular injection. Proper dosage of these drugs and the timing of egg recovery require monitoring of the ovarian response, usually by way of blood tests and ultrasound examinations during the ovarian stimulation.

As with all injectable medications, bruising, redness, swelling, or discomfort can occur at the injection site. Rarely, there can be an allergic reaction to these drugs. The intent of giving these medications is to mature multiple follicles, and many women experience some bloating and minor discomfort as the follicles grow and the ovaries become temporarily enlarged. Up to 2.0% of women will develop Ovarian Hyperstimulation Syndrome (OHSS) [see full discussion of OHSS in the Risks to Women section which follows]. Other risks and side effects of gonadotropins include, but are not limited to, fatigue, headaches, weight gain, mood swings, nausea, ovarian torsion, and clots in blood vessels.

Even with pre-treatment attempts to assess the potential response of the ovaries, the stimulation may result in the development of very few follicles. The end result may be few or no eggs obtained at egg retrieval, or even cancellation of the treatment cycle prior to egg retrieval.

Some research suggested that the risk of ovarian tumors may increase in women who take any fertility drugs over a long period of time. These studies had significant flaws which limited the strength of the conclusions. More recent studies have not confirmed this risk. A major risk factor for ovarian cancer is infertility per se, suggesting that early reports may have falsely attributed the risk resulting from infertility to the use of medications to overcome it. In these studies, conception lowered the risk of ovarian tumors to that of fertile women.

- **GnRH-agonists (Leuprolide acetate)**: This medication is taken by injection. The primary role of this medication is to prevent a premature LH surge, which could result in the release of eggs before they are retrieved. Since GnRH-agonists initially cause a release of FSH and LH from the
pituitary, they can also be used to start the growth of the follicles (a “flare” protocol) or initiate the final stages of egg maturation. Though leuprolide acetate is an FDA (Food Drug Administration) approved medication, it has not been approved for use in IVF, although it has routinely been used in this way for more than 20 years. Potential side effects usually experienced with long-term use include, but are not limited to, hot flashes, vaginal dryness, bone loss, nausea, vomiting, skin reactions at the injection site, fluid retention, muscle aches, headaches, depression, and a change in timing and characteristics of the menstrual cycle. No long term or serious side effects are known. Since GnRH-a are oftentimes administered after ovulation, it is possible that they will be taken early in pregnancy. The safest course of action is to use a barrier method of contraception (condoms) the month you will be starting the GnRH-a. GnRH-a have not been associated with any fetal malformations, however, you should discontinue use of the GnRH-a as soon as pregnancy is confirmed.

- **GnRH-antagonists**: These are another class of medications used to prevent premature ovulation. They tend to be used for short periods of time in the late stages of ovarian stimulation. The potential side effects include, but are not limited to, abdominal pain, headaches, skin reaction at the injection site, and nausea.

- **Human chorionic gonadotropin (hCG)**: hCG is a natural hormone used in IVF to induce the eggs to become mature and fertilizable. The timing of this medication is critical to retrieve mature eggs. Potential side effects include, but are not limited to, breast tenderness, bloating, and pelvic discomfort.

- **Progesterone, and in some cases, estradiol**: Progesterone and estradiol are hormones normally produced by the ovaries. After egg retrieval, the ovaries may not produce adequate amounts of these hormones to fully support a pregnancy. Accordingly, supplemental progesterone, and in some cases estradiol, are given to ensure adequate hormonal support of the uterine lining. Progesterone is usually given by injection, orally, or by the vaginal route after egg retrieval. Progesterone is often continued for several weeks after a pregnancy has been confirmed. Progesterone has not been associated with an increase in fetal abnormalities. Side effects of progesterone include symptoms of depression, sleepiness, allergic reaction. If given by intra-muscular injection there may be pain at the injection site and a very small risk of infection.

- Estradiol, if given, can be by oral, trans-dermal, intramuscular, or vaginal administration. Side effects of estradiol include nausea, irritation at the injection site if given by the trans-dermal route, and the risk of blood clots or stroke.

- **Oral contraceptive pills**: Many treatment protocols include oral contraceptive pills to be taken for 2 to 5 weeks before lupron or gonadotropin injections are started. Side effects include unscheduled bleeding, headache, breast tenderness, nausea, swelling, and the risk of blood clots or stroke.

- **Other medications**: Antibiotics may be given to reduce the risk of infection associated with egg retrieval. Antibiotic use may be associated with causing a yeast infection, nausea, vomiting, diarrhea, rashes, sensitivity to the sun, and allergic reactions.

- Anti-anxiety medications or muscle relaxants may be recommended prior to the embryo transfer; the most common side effect is drowsiness. Other medications such as steroids, heparin, low molecular weight heparin or aspirin may also be included in the treatment protocol.
b. Transvaginal Oocyte Retrieval

- Eggs are removed from the ovary with a needle under ultrasound guidance
- Anesthesia is provided to make this comfortable
- Injury and infection are rare

Oocyte retrieval is the removal of eggs from the ovary. A transvaginal ultrasound probe is used to visualize the ovaries and follicles within the ovaries. A long needle is guided into each follicle and the contents aspirated. The aspirated material includes follicular fluid, oocytes (eggs), and granulosa (egg-supporting) cells. Rarely the ovaries are not accessible by the transvaginal route and laparoscopy or transabdominal retrieval is necessary. Anesthesia is generally used to reduce if not eliminate discomfort. Risks of egg retrieval include:

**Infection**: Bacteria normally present in the vagina may be inadvertently transferred into the abdominal cavity by the needle. These bacteria may cause an infection of the uterus, fallopian tubes, ovaries or other intra-abdominal organs. The estimated incidence of infection after egg retrieval is less than 0.5%. Treatment of infections could require the use of oral or intravenous antibiotics. Severe infections occasionally require drainage or surgery to remove infected tissue. Infections can have a negative impact on future fertility. Prophylactic antibiotics are sometimes used at the time of the egg retrieval procedure to reduce the risk of pelvic or abdominal infection. Despite the use of antibiotics, there is no way to eliminate this risk completely.

**Bleeding**: The needle passes through the vaginal wall and into the ovary to obtain the eggs. Both of these structures contain blood vessels. In addition, there are other blood vessels nearby. Small amounts of blood loss are common during egg retrievals. The incidence of major bleeding problems has been estimated to be less than 0.1%. Major bleeding may require surgical repair, blood transfusion, and possibly loss of the ovary. Although very rare, unrecognized bleeding has lead to death.

**Trauma**: Despite the use of ultrasound guidance, it is possible to damage other intra-abdominal organs during the egg retrieval. Previous reports in the medical literature have noted damage to the bowel, appendix, bladder, ureters, and ovary. Damage to internal organs may result in the need for additional treatment such as surgery for repair or removal of the damaged organ. However, the risk of such trauma is low.

**Anesthesia**: The use of anesthesia during the egg retrieval can produce unintended complications such as an allergic reaction, low blood pressure, nausea or vomiting, and in rare cases, death.

**Failure**: It is possible that the aspiration will fail to obtain any eggs, or the eggs may be abnormal or of poor quality and otherwise fail to fertilize or to produce a viable pregnancy.

c. In vitro fertilization and embryo culture

- Sperm and eggs are placed together in specialized conditions (culture media, controlled temperature, humidity and light) in hopes of fertilization
- Culture medium is designed to permit normal fertilization and early embryo development, but the content of the medium is not standardized.
- Embryo development in the lab helps distinguish embryos with more potential from those with less or none.
After eggs are retrieved, they are transferred to the embryology laboratory where they are kept in conditions that support their needs and growth. The eggs are placed in small dishes or tubes containing "culture medium," a special fluid developed to support development of eggs and embryos made to resemble that found in the fallopian tube or uterus. The dishes containing the embryos are then placed into incubators, which control the temperature and atmospheric gasses the embryos experience.

A few hours after eggs are retrieved, sperm are placed in the culture medium with the eggs, or individual sperm are injected into each mature egg in a technique called Intracytoplasmic Sperm Injection (ICSI) (see below). The inseminated eggs are then returned to the incubator, where they remain to develop potentially into embryos. Periodically over the next few days, the dishes are inspected so the development of the embryos can be assessed. The following day after eggs have been inseminated or injected with a single sperm (ICSI), they are examined for signs that the process of fertilization is underway. At this stage, normal development is evident by the still single cell having 2 nuclei; this stage is called a zygote. Two days after insemination or ICSI, normal embryos have divided into about 4 cells. Three days after insemination or ICSI, normally developing embryos contain about 8 cells. Five days after insemination or ICSI, normally embryos have developed to the blastocyst stage, which is typified by an embryo that now has 80 or more cells, an inner fluid-filled cavity, and a small cluster of cells called the inner cell mass.

It is important to note that since many eggs and embryos are abnormal, it is expected that not all eggs will fertilize and not all embryos will divide at a normal rate. The chance that a developing embryo will produce a pregnancy is related to whether its development in the lab is normal, but this correlation is not perfect. This means that not all embryos developing at the normal rate are in fact also genetically normal, and not all poorly developing embryos are genetically abnormal. Nonetheless, their visual appearance is the most common and useful guide in the selection of the best embryo(s) for transfer.

In spite of reasonable precautions, any of the following may occur in the lab that would prevent the establishment of a pregnancy:

- Fertilization of the egg(s) may fail to occur. Please note that if there is complete fertilization failure following insemination of eggs, an "ICSI rescue" procedure will be performed on the following morning. In this procedure we will attempt to fertilize any mature eggs using ICSI.
- The male partner may be unable to produce a sperm sample for fertilization. Because of this risk, we suggest that patients bank a "back-up" sperm specimen prior the the ART cycle.
- One or more eggs may be fertilized abnormally resulting in an abnormal number of chromosomes in the embryo; these abnormal embryos will not be transferred.
- The fertilized eggs may degenerate before dividing into embryos, or adequate embryonic development may fail to occur.
- Bacterial contamination or a laboratory accident may result in loss or damage to some or all of the eggs or embryos.
- Laboratory equipment may fail, and/or extended power losses can occur which could lead to the destruction of eggs, sperm and embryos.
- Other unforeseen circumstances may prevent any step of the procedure to be performed or prevent the establishment of a pregnancy.
- Hurricanes, floods, or other unexpected events (including bombnings or other terrorist acts) could destroy the laboratory or its contents, including any sperm, eggs, or embryos being stored there.

Quality control in the lab is extremely important. Sometimes immature or unfertilized eggs, sperm or abnormal embryos (abnormally fertilized eggs or embryos whose lack of development indicates they are not of sufficient quality to be transferred) that would normally be discarded can be used for quality control. You are being asked to allow the clinic to use this material for quality control purposes before being discarded in accordance with normal laboratory procedures and applicable laws. None of this material will
be utilized to establish a pregnancy or a cell line unless you sign other consent forms to allow the clinic to use your eggs, sperm or embryos for research purposes. Please initial your choice or A or B below:

A. ______ ______I/We hereby ACCEPT to allow the clinic to utilize my/our immature or unfertilized eggs, left-over sperm or abnormal embryos for quality control and training purposes before they are discarded.

B. ______ ______I/We hereby DO NOT ACCEPT to allow the clinic to utilize my/our immature or unfertilized eggs, left-over sperm or abnormal embryos for quality control and training purposes. This material will be discarded in accordance with normal laboratory procedures and applicable laws.

d. Embryo transfer

- After a few days of development, the best appearing embryos are selected for transfer
- The number chosen influences the pregnancy rate and the multiple pregnancy rate
- A woman’s age and the appearance of the developing embryo have the greatest influences on pregnancy outcome
- Embryos are placed in the uterine cavity with a thin tube (catheter)
- Excess embryos of sufficient quality that are not transferred can be frozen

After a few days of development, one or more embryos are selected for transfer to the uterine cavity. Embryos are placed in the uterine cavity with a thin tube (catheter). Ultrasound guidance is used to help guide the catheter and confirm placement through the cervix and into the uterine cavity. Although the possibility of a complication from the embryo transfer is very rare, risks include infection and loss of, or damage to the embryos.

The number of embryos transferred influences the pregnancy rate and the multiple pregnancy rate. The age of the woman and the appearance of the developing embryo have the greatest influence on pregnancy outcome and the chance for multiple pregnancy. While it is possible, it is unusual to develop more fetuses than the number of embryos transferred.

In an effort to help curtail the problem of multiple pregnancies (see multiple pregnancies), national professional guidelines recommend limits on the number of embryos to transfer (see Appendix). These limits differ depending on the developmental stage of the embryos and the quality of the embryos and take into account the patient’s personal history.

In some cases, there will be additional embryos remaining in the lab after the transfer is completed. If the embryos have developed normally, it may be possible to freeze them for later use. (See section 2.c. for an in-depth discussion of embryo freezing).

_____ _____We/I agree to the transfer of up to ___________ embryos per cycle.

_____ _____We/I agree to single embryo transfer if conditions are met to do so.
**e. Hormonal support of uterine lining**

- Successful attachment of embryo(s) to the uterine lining depends on adequate hormonal support
- Progesterone, given by the intramuscular or vaginal route, is routinely given for this purpose

Successful attachment of embryos to the uterine lining depends on adequate hormonal support of the lining. The critical hormones in this support are progesterone and estradiol. Normally, the ovary makes sufficient amounts of both hormones. However, in IVF cycles, this support is not always adequate. Therefore, progesterone is routinely given, and some clinics also prescribe estradiol. Progesterone is given by the intramuscular or vaginal route. Estradiol is given by the oral, vaginal, or intramuscular route. The duration of this support is from 2 to 10 weeks.

**2. Additional Elements and their risk**

**a. Intracytoplasmic Sperm Injection (ICSI)**

- ICSI is used to increase the chance of fertilization when fertilization rates are anticipated to be lower than normal
- Overall success rates with ICSI are slightly lower than for conventional insemination
- An increased risk of genetic defects in offspring is reported
- ICSI will not improve oocyte defects

The use of ICSI may provide an effective treatment for male factor infertility or prior poor fertilization. ICSI involves the direct injection of a single sperm into the interior of an egg using an extremely thin glass needle. This technique bypasses the shell around the egg (zona pellucida) and the egg membrane (oolemma) to deliver the sperm directly into the egg. ICSI may allow couples with male factor infertility to achieve fertilization and live birth rates close to those achieved with in vitro fertilization (IVF) using conventional methods of fertilization in men with normal sperm counts. ICSI can be performed even in men with no sperm in the ejaculate if sperm can be successfully collected from the epididymis or the testis.

Reports on the risk of birth defects associated with ICSI (compared to those associated with conventional fertilization in IVF cycles) have yielded conflicting results. The most comprehensive study conducted thus far, based on data from five-year-old children, has suggested that ICSI is associated with an increased risk of certain major congenital anomalies. However, whether the association is due to the ICSI procedure itself, or to inherent sperm defects, could not be determined because the study did not distinguish between male factor conditions and other causes of infertility. Even if there is an increased risk of congenital malformations in children conceived with ICSI, the risk is relatively low (4.2% versus -3% of those conceived naturally). The effect of ICSI on the intellectual and motor development of children conceived via ICSI also has been controversial. An early report suggested that development in such children lagged significantly behind that of children resulting from conventional IVF or those conceived naturally. However, more recent studies from larger groups using standardized criteria for evaluation have not detected any differences in the development or the abilities of children born after ICSI, conventional IVF, or natural conception.

The prevalence of sex chromosome abnormalities in children conceived via ICSI is higher than observed in the general IVF population, but the absolute difference between the two groups is small (0.8% to 1.0% in ICSI offspring vs. 0.2% in the general IVF population). The reason for the increased prevalence of chromosomal anomalies observed in ICSI offspring is not clear. Whereas it may result from the ICSI
procedure itself, it might also reflect a direct paternal effect. Men with sperm problems (low count, poor motility, and/or abnormal shape) are more likely themselves to have genetic abnormalities and often produce sperm with abnormal chromosomes; the sex chromosomes (X and Y) in the sperm of men with abnormal semen parameters appear especially prone to abnormalities. If sperm with abnormal chromosomes produce pregnancies, these pregnancies will likely carry these same defects. The prevalence of translocations (a re-arrangement of chromosomes that increases the risk of abnormal chromosomes in egg or sperm and can cause miscarriage) of paternal origin and of de novo balanced translocations in ICSI offspring (0.36%) also appears higher than in the general population (0.07%).

Some men are infertile because the tubes connecting the testes to the penis did not form correctly. This condition, called congenital bilateral absence of the vas deferens (CBAVD), can be bypassed by aspirating sperm directly from the testicles or epididymis and using them in IVF with ICSI to achieve fertilization. However, men with CBAVD are affected with a mild form of cystic fibrosis (CF), and this gene will be passed on to their offspring. All men with CVABD, as well as their partners, should be tested for CF gene mutations prior to treatment, so that the risk of their offspring having CF can be estimated and appropriate testing performed. It is important to understand that there may be CF gene mutations that are not detectable by current testing and parents who test negative for CF mutations can still have children affected with CF.

Some men have no sperm in their ejaculate because their testes do not produce adequate quantities (non-obstructive azoospermia). This can be due to a number of reasons such as prior radiation, chemotherapy or undescended testicles. In some men, small deletions on their Y chromosomes lead to extremely low or absent sperm counts. Testicular biopsy and successful retrieval of viable sperm can be used to fertilize eggs with ICSI. However, any sperm containing a Y chromosomal microdeletion will be transmitted to the offspring. Thus the risk that male offspring might later manifest disorders including infertility is very real. However, men without a detectable deletion by blood testing can generate offspring having a Y chromosome microdeletion, because the chromosomes in the sperm may not be the same as those seen when tested by a blood test.

b. Assisted Hatching

- Assisted Hatching involves making a hole in the outer shell (zona pellucida) that surrounds the embryo
- Hatching may make it easier for embryos to escape from the shell which surrounds them.

The cells that make up the early embryo are enclosed within a flexible membrane (shell) called the zona pellucida. During normal development, a portion of this membrane dissolves, allowing the embryonic cells to escape or “hatch” out of the shell. Only upon hatching can the embryonic cells implant within the wall of the uterus to form a pregnancy.

Assisted hatching is the laboratory technique in which an embryologist makes an artificial opening in the shell of the embryo. The hatching is usually performed on the day of transfer, prior to loading the embryo into the transfer catheter. The opening can be made by mechanical means (slicing with a needle or burning the shell with a laser) or chemical means by dissolving a small hole in the shell with a dilute acid solution.

Some programs have incorporated artificial or “assisted hatching” into their treatment protocols because they believe it improves implantation rates, and ultimately, live birth rates, although definitive evidence of this is lacking.

Risks that may be associated with assisted hatching include damage to the embryo resulting in loss of embryonic cells, or destruction or death of the embryo. Artificial manipulation of the zygote may
increase the rates of monozygotic (identical) twinning which are significantly more complicated pregnancies. There may be other risks not yet known.

c. Embryo freezing

- Freezing of viable embryos not transferred after egg retrieval provide additional chances for pregnancy.
- Frozen embryos do not always survive the process of freezing and thawing.
- Freezing of eggs before fertilization is currently much less successful than freezing of fertilized eggs (embryos).
- Ethical and legal dilemmas can arise when couples separate or divorce; disposition agreements are essential.
- It is the responsibility of each couple with frozen embryos to remain in contact with the clinic on an annual basis.

Freezing (or “cryopreservation”) of embryos is a common procedure. Since multiple eggs (oocytes) are often produced during ovarian stimulation, on occasion there are more embryos available than are considered appropriate for transfer to the uterus. These embryos, if viable, can be frozen for future use. This saves the expense and inconvenience of stimulation to obtain additional eggs in the future. Furthermore, the availability of embryo freezing permits patients to transfer fewer embryos during a fresh cycle, reducing the risk of high-order multiple gestations (triplets or greater). Other possible reasons for freezing of embryos include freezing all embryos in the initial cycle to prevent severe ovarian hyperstimulation syndrome (OHSS), or if a patient is concerned that her future fertility potential might be reduced due to necessary medical treatment (e.g., cancer therapy or surgery). The pregnancy success rates for frozen embryos transferred into the human uterus can vary from practice to practice. Overall pregnancy rates at the national level with frozen embryos are lower than with fresh embryos.

**Indications:**
- To reduce the risks of multiple gestation
- To preserve fertility potential in the face of certain necessary medical procedures
- To increase the chance of having one or more pregnancies from a single cycle of ovarian stimulation
- To minimize the medical risk and cost to the patient by decreasing the number of stimulated cycles and egg retrievals
- To reduce the risk of OHSS by temporarily delaying pregnancy and freezing all embryos when the OHSS risk is high.

**Risks of embryo freezing:** Traditional methods of embryo freezing include “slow,” graduated freezing in a computerized setting, and “rapid” freezing methods, called “vitrification.” Current techniques deliver a high percentage of viable (live) embryos thawed after freezing, but there can be no certainty that embryos will thaw normally, nor be viable enough to divide and eventually implant in the uterus. Embryo freezing techniques could theoretically be injurious to the embryo. Extensive animal data and limited human data, do not indicate any likelihood that children born of embryos that were frozen and thawed will experience greater risk of abnormalities than those born of fresh embryos. However, until very large numbers of children have been born following freezing and thawing of embryos, it is not possible to be certain that the rate of abnormalities is no different from the normal rate.

DHMC will store frozen embryos no longer than 5 years. If pregnancy is not achieved, we expect the embryos to be used within one year. In agreeing to store frozen embryos, DHMC acknowledges that, in general, decisions regarding the use and disposition of any such frozen embryos remain with the participants provided that, where there are two participants, both must consent to any action that is taken, and that their choice is limited to the following options:

Initials: Patient __________________ Partner (if applicable) __________________ 10

Health Information Services Approval: 4/11/2012  Version Date: 4/11/2012
1) Discarding your frozen embryo(s)
2) Donating your frozen embryo(s) for approved research studies.
3) Donating your frozen embryos to another couple in order to attempt pregnancy (You will be asked to undergo additional infectious disease testing and screening recommended by the FDA if you select this option.)
4) Shipping your frozen embryos to another assisted reproductive technology (ART) clinic or to long term storage.

Because of the possibility that you and/or your partner could disagree, separate, divorce, die or become incapacitated, it is important to decide on the disposition of any embryo(s), fresh or frozen that remain in the laboratory. Please initial your choices below:

<table>
<thead>
<tr>
<th>Patient</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Discard the frozen embryo(s)</td>
<td></td>
</tr>
<tr>
<td>2) Donate the frozen embryo(s) for research</td>
<td></td>
</tr>
<tr>
<td>3) Donate the frozen embryos to another couple</td>
<td></td>
</tr>
<tr>
<td>4) In case of incapacity or death: Allow your partner to use the embryos in any manner that he/she wishes</td>
<td></td>
</tr>
</tbody>
</table>

**d. Embryo disposition storage exceptions**

With the exception of the conditions listed below, DHMC will not offer frozen embryos to a donee, release them to another physician or facility or intentionally discard an embryo without your prior written consent.

However, our staff **may take action with respect to an embryo (including discard), without having first obtained your consent** in the following situations:

(a) the embryo has been stored at DHMC for a total of 5 years and you have been unable or unwilling to make arrangements to transfer the embryos to another ART program or long term storage facility;

(b) the embryo has been frozen for one year or more and you have not responded within 30 days to a certified letter sent to the last address known to us requesting consent to a disposition of the embryo.
Note: Continued storage for over one year must be reconfirmed in writing by participants on a yearly basis;

(c) non-payment of storage fees or other hospital bills. Failure to pay storage fees or failure to make appropriate arrangements with our Patient Financial Services office to pay preexisting bills may result in discard of stored embryos.

Additionally, DHMC staff **may take action with respect to an embryo without having first obtained the consent of you or your partner (if any) under the following circumstances:**

(i) One participant has requested a particular disposition and the other can not or will not consent for any reason including, but not limited to, the death, mental incapacity or absence (by virtue of divorce, separation or abandonment) of the other; failure of the other to respond within 30 days to a notice sent to him or her by DHMC staff; or the fact that the other participant desires that a different disposition of the embryo(s) be made; or
(ii) You and/or your partner (if any) would like to take action with respect to your frozen embryos that DHMC staff do not agree with. For example, you insist upon the donation of your frozen embryo(s) but, in the opinion of DHMC staff, such a donation is inadvisable.

Before an action is taken regarding the disposition of any embryos (unless otherwise required by law), DHMC staff will send notice to the participants, at the last address known to DHMC staff.

It is anticipated that, under some circumstances, DHMC staff will decide to take action with respect to frozen embryos to which the participants have not consented. For instance, DHMC staff might decide to thaw and discard certain embryos even though the participant(s) have asked DHMC staff to continue to store the frozen embryos. DHMC retains discretion to take any action it chooses within the guidelines set forth herein unless ordered otherwise by a court of competent jurisdiction. Such action may include thawing and discarding the embryos. It would NOT include donating the embryos for use by another couple or for embryo research.

Finally, it is possible that DHMC may be required by law or court order to make a disposition of embryos without first obtaining the consent of the participants or following the other procedures set forth herein. In this event, DHMC will attempt to notify the participants in advance of taking the action, unless to do so would be impossible or unreasonable under the circumstances.

Each participant is responsible for notifying DHMC ART Program staff, in writing, of any change in his or her address and marital status if changed. Any notices required to be given to the participants by DHMC will be deemed to have been given upon mailing to the last address(es) provided to us.

e. Donated or research embryo fate

In certain situations, donating embryo(s) for research or to another couple may not be possible or may be restricted by law. While efforts will be made to abide by your wishes, no guarantees can be given that embryo(s) will be used for research or donated to another couple. In these instances, if no recipient or research project can be found, or your embryos are not eligible, your embryo(s) will be discarded by the lab in accordance with laboratory procedures and applicable laws.

B. Risks to the Woman

1. Ovarian Hyperstimulation Syndrome

To increase the number of eggs that develop, a series of hormone shots is given. One the most serious side effects of ovarian stimulation is ovarian hyperstimulation syndrome (OHSS). Its symptoms can include increased ovarian size, nausea and vomiting, accumulation of fluid in the abdomen, breathing difficulties, an increased concentration of red blood cells, kidney and liver problems, and in the most severe cases, blood clots, kidney failure, or death. The severe cases affect only a very small percentage of women who undergo in vitro fertilization—0.2 percent or less of all treatment cycles—and the very severe are an even smaller percentage. For example, only about 1.4 in 100,000 cycles has lead to kidney failure. OHSS occurs at two stages: early, 1 to 5 days after egg retrieval (as a result of the hCG trigger); and late, 10 to 15 days after retrieval (as a result of the hCG if pregnancy occurs). The risk of severe complications is about 4 to 12 times higher if pregnancy occurs. To reduce this risk, embryo transfer may not be performed, in which case all embryos will be frozen for future use.
2. Cancer

Many have worried that the use of fertility drugs could lead to an increased risk of cancer—in particular, breast, ovarian, and uterine (including endometrial) cancers. One must be careful in interpreting epidemiological studies of women taking fertility drugs, because all of these cancers are more common in women with infertility, so merely comparing women taking fertility drugs with women in the general population inevitably shows an increased incidence of cancer. When the analysis takes into account the increased cancer risk due to infertility per se, the evidence does not support a relationship between fertility drugs and an increased prevalence of breast or ovarian cancer. More research is required to examine the long-term impact fertility drugs may have on breast and ovarian cancer prevalence rates. For uterine cancer, the numbers are too small to achieve statistical significance, but it is at least possible that use of fertility drugs may indeed cause some increased risk of uterine cancer.

3. Risks of Pregnancy

Pregnancies that occur with IVF are associated with increased risks of certain conditions (see Appendix). Some of these risks stem from the higher average age of women pregnant by IVF and the fact that the underlying cause of infertility may be the cause of the increased risk of pregnancy complications. See Appendix for a list of possible pregnancy risks and their rates of occurrence. There may also be a slightly increased rate of miscarriage after ART.

Currently more than 30% of IVF pregnancies are twins or higher-order multiple gestations (triplets or greater), and about half of all IVF babies are a result of multiple gestations. Identical twinning occurs in 1.5% to 4.5% of IVF pregnancies. IVF twins deliver on average three weeks earlier and weigh 1,000 gm less than IVF singletons. Of note, IVF twins do as well as spontaneously conceived twins. Triplet (and greater) pregnancies deliver before 32 weeks (7 months) in almost half of cases.

Additionally, while embryos are transferred directly into the uterus with IVF, ectopic (tubal, cervical and abdominal) pregnancies as well as abnormal intra-uterine pregnancies have occurred either alone or concurrently with a normal intra-uterine pregnancy. These abnormal pregnancies oftentimes require medical treatments with methotrexate (a weak chemotherapy drug) or surgery to treat the abnormal pregnancy.

C. Risks to Offspring

- IVF babies may be at a slight increased risk for birth defects
- The risk for a multiple pregnancy is significantly higher for patients undergoing IVF, even when only one embryo is transferred
- Multiple pregnancies are the greatest risk for babies following IVF
- Some risk may also stem from the underlying infertile state, or from the IVF techniques, or both

1. Overall risks.

Since the first birth of an IVF baby in 1978, more than 3 million children have been born worldwide following IVF treatments. Numerous studies have been conducted to assess the overall health of IVF children and the majority of studies on the safety of IVF have been reassuring. A major problem in interpreting the data arises from the fact that comparing a group of infertile couples to a group of normally fertile couples is not the proper comparison. Infertile couples, by definition, do not have normal reproductive function and might be expected to have babies with more abnormalities than a
group of normally fertile couples. This said, even if the studies suggesting an increased risk to babies born after IVF prove to be true, the absolute risk of any abnormal outcome appears to be small.

Singletons conceived with IVF tend to be born slightly earlier than naturally conceived babies (39.1 weeks as compared to 39.5 weeks). IVF twins are not born earlier or later than naturally conceived twins. The risk of a singleton IVF conceived baby being born with a birth weight under 5 pounds nine ounces (2500 grams) is 12.5% vs. 7% in naturally conceived singletons.

2. Birth Defects.

The risk of birth defects in the normal population is 2-3%. In IVF babies the birth defect rate may be 2.6-3.9%. The difference is seen predominately in singleton males. Studies to date have not been large enough to establish a correlation between IVF treatment and specific types of birth defects.

*Imprinting Disorders.* These are rare disorders having to do with whether a maternal or paternal gene is inappropriately expressed. In two studies approximately 4% of children with the imprinting disorder called Beckwith-Weidemann Syndrome were born after IVF, which is more than expected. A large Danish study however found no increased risk of imprinting disorders in children conceived with the assistance of IVF. Since the incidence of this syndrome in the general population is 1/15,000, even if there is a 2 to 5-fold increase to 2-5/15,000, this absolute risk is very low.

*Childhood cancers.* Most studies have not reported an increased risk with the exception of a rare tumor called retinoblastoma.

*Infant Development.* In general, studies of long-term developmental outcomes have been reassuring so far; most children are doing well. However, these studies are difficult to do and suffer from limitations. A more recent study with better methodology reports an increased risk of cerebral palsy (3.7 fold) and developmental delay (4 fold), but most of this stemmed from the prematurity and low birth weight that was a consequence of multiple pregnancy. There may be risks to infants even in singleton pregnancies. A summary of these risks and the rate of risk can be found in the Appendix.

3. Risks of a Multiple Pregnancy

The most important maternal complications associated with multiple gestation are preterm labor and delivery, pre-eclampsia, and gestational diabetes (see prior section on Risks to Woman). Triplets and above increase the risk to the mother of more significant complications including post-partum hemorrhage and transfusion.

Prematurity accounts for most of the excess perinatal morbidity and mortality associated with multiple gestations. Moreover, IVF pregnancies are associated with an increased risk of prematurity, independent of maternal age and fetal numbers. Fetal growth problems and discordant growth among the fetuses also result in perinatal morbidity and mortality. Multifetal pregnancy reduction (where one or more fetuses are selectively terminated) reduces, but does not eliminate, the risk of these complications.

The death of one or more fetuses in a multiple gestation (vanishing twin) is more common in the first trimester and may be observed in up to 25% of pregnancies after IVF. Loss of a fetus in the first trimester is unlikely to adversely affect the surviving fetus or mother. No excess perinatal or maternal morbidity has been described resulting from a “vanishing” embryo.

Demise of a single fetus in a twin pregnancy after the first trimester is more common when they share a placenta, ranging in incidence from 0.5% to 6.8%, and may cause harm to the remaining fetus.
Multiple fetuses (including twins) that share the same placenta have additional risks. Twin-twin transfusion syndrome in which there is an imbalance of circulation between the fetuses may occur in up to 20% of twins sharing a placenta. Excess or insufficient amniotic fluid may result from twin-to-twin transfusion syndrome. Twins sharing the same placenta have a higher frequency of birth defects compared to pregnancies having two placentas. Twins sharing the same placenta appear to occur more frequently after blastocyst transfer.

Placenta previa and vasa previa are more common complications in multiple gestations. Abruptio placenta also is more common and postpartum hemorrhage may complicate 12% of multifetal deliveries. Consequences of multiple gestations include the major sequelae of prematurity (cerebral palsy, retinopathy of prematurity, and chronic lung disease) as well as those of fetal growth restriction (polycythemia, hypoglycemia, necrotizing enterocolitis). It is unclear to what extent multiple gestations themselves affect neuro-behavioral development in the absence of these complications. Rearing of twins and high-order multiples may generate physical, emotional, and financial stresses, and the incidence of maternal depression and anxiety is increased in women raising multiples. At mid-childhood, prematurely born offspring from multiple gestations have lower IQ scores, and multiple birth children have an increase in behavioral problems compared with singletons. It is not clear to what extent these risks are affected by IVF per se.

**The Option of Selective Reduction:** Pregnanacies that have more than 2 fetuses are considered an adverse outcome of infertility treatment. The greater the number of fetuses within the uterus, the greater is the risk for adverse perinatal and maternal outcomes. Patients with more than twins are faced with the options of continuing the pregnancy with all risks previously described, terminating the entire pregnancy, or reducing the number of fetuses in an effort to decrease the risk of maternal and perinatal morbidity and mortality. Multifetal pregnancy reduction (MFPR) decreases risks associated with preterm delivery, but often creates profound ethical dilemmas. Pregnancy loss is the main risk of MFPR. However, current data suggest that such complications have decreased as experience with the procedure has grown. The risk of loss of the entire pregnancy after MFPR is approximately 1%.

**D. Ethical and Religious Considerations in Infertility Treatment**

Infertility treatment can raise concerns and questions of an ethical or religious nature for some patients. The technique of in vitro fertilization (IVF) involves the creation of human embryos outside the body, and can involve the production of excess embryos and/or ‘high-order’ multiple pregnancy (triplets or more). We encourage patients and their spouses or partners who so desire to consult with trusted members of their religious or ethics community for guidance on their infertility treatment.

**E. Psychosocial Effects of Infertility Treatment**

A diagnosis of infertility can be a devastating and life-altering event that impacts on many aspects of a patient’s life. Infertility and its treatment can affect a patient and her spouse or partner medically, financially, socially, emotionally and psychologically. Feelings of anxiousness, depression, isolation, and helplessness are not uncommon among patients undergoing infertility treatment. Strained and stressful relations with spouses, partners and other loved ones are not uncommon as treatment gets underway and progresses.

Our health care team is available to address the emotional, as well as physical, symptoms that can accompany infertility. In addition to working with our health care team to minimize the emotional impacts of infertility treatments, patients may also consider working with mental health professionals who are specially trained in the area of infertility care.
While it is normal to experience emotional ups and downs when pursuing infertility treatment, it is important to recognize when these feelings are of a severe nature. If you experience symptoms of depression over a prolonged period of time, you may benefit from working with a mental health professional. Symptoms may include but are not limited to loss of interest in usual activities, difficulty with concentration, sadness that does not lift, and difficulty concentrating or sleeping. Our health care team can assist you in locating a qualified mental health professional who is familiar with the emotional experience of infertility, or you can contact a national support group such as RESOLVE, (www.resolve.org, Tel. 1-888-623-0744) or The American Fertility Association (AFA), (www.theafa.org, Tel: 1-888-917-3777).

F. Legal Considerations and Legal Counsel

The law regarding embryo freezing, subsequent thaw and use, and parent-child status of any resulting child(ren) is, or may be, unsettled in the state in which either the patient, spouse, partner, or any donor currently or in the future lives, or the state in which the ART Program is located. We acknowledge that the ART Program has not given us legal advice, that we are not relying on the ART Program to give us any legal advice, and that we have been informed that we may wish to consult a lawyer who is experienced in the areas of reproductive law and embryo freezing and disposition if we have any questions or concerns about the present or future status of our embryos, our individual or joint access to them, our individual or joint parental status as to any resulting child, or about any other aspect of this consent and agreement.

G. Alternatives to IVF

There are alternatives to IVF treatment including adoption, child free living, and the use of donor sperm, donor egg, or donor embryo. Sperm freezing, but not egg freezing, has been an established procedure for many decades. Egg freezing is considered an experimental procedure at this time.

H. Reporting Outcomes

The 1992 Fertility Clinic Success Rate and Certification Act requires the Centers for Disease Control and Prevention (CDC) to collect cycle-specific data as well as pregnancy outcome on all assisted reproductive technology cycles performed in the United States each year and requires them to report success rates using these data. Consequently, data from my/our IVF procedure will be provided to the CDC, and to the Society of Assisted Reproductive Technologies (SART) of the American Society of Reproductive Medicine (ASRM) (if my/our clinic is a member of this organization). The CDC may request additional information from the treatment center or contact the me/us directly for additional follow-up. Additionally, my/our information may be used and disclosed in accordance with HIPAA guidelines in order to perform research or quality control. All information used for research will be de-identified prior to publication. De-identification is a process intended to prevent the data associated with my/our treatment being used to identify me/us as individuals.

As part of this reporting requirement, it is your responsibility as participant(s) to keep the DHMC ART Program staff informed of the outcome of our participation. By signing this form you are also giving DHMC staff permission to contact your obstetrician to obtain birth information.

I. Donated Gametes
The following are important aspects of egg or sperm donation:

**For egg donation:** ONCE A DONOR'S EGGS HAVE BEEN REMOVED FROM THE DONOR'S BODY, ALL DECISIONS ABOUT THE EGGS WILL BE MADE SOLELY BY THE RECIPIENT, HER PARTNER, IF ANY, AND/OR THE DHMC ART PROGRAM.

DONORS MUST UNDERSTAND THAT, FROM THIS TIME FORWARD, THEY HAVE NO CONTROL OVER THE USE OR DISPOSITION OF THEIR EGGS OR THE RESULTING EMBRYOS, EXCEPT THAT THE EGGS OR EMBRYOS WILL BE USED IN ACCORDANCE WITH THIS PROCEDURE DESCRIPTION.

Recipients of donor eggs or donor sperm should be aware that according to New Hampshire law, once they sign this consent form, they will be the legal parents of any child born of that ART procedure regardless of the use of donor eggs or sperm. (Note: Special considerations apply to surrogacy/ gestational carrier cycles as described in the consent for that procedure.)

Donors of sperm, eggs, or embryos will be medically screened. It is important that participants realize that, although this screening takes place, there is a risk that the woman participating in IVF will contract a sexually transmitted disease, including AIDS, as a result of the embryo transfer. In addition, certain of these diseases, including AIDS, can be communicated to a fetus or to a child during childbirth as well as to your sexual partner.

If donated sperm, eggs, or embryos are used, there is also a risk that donors will carry genetic or family disorders that could be passed along to the child. Although donors will be screened for genetic problems, DHMC cannot be guaranteed that all donors are free of such genetic problems.

**J. Additional Understandings and Signatures**

We/I understand that the Dartmouth-Hitchcock Medical Center, its component institutions, and the DHMC ART Program do not provide financial compensation or reimbursement for medical care in the event that our participation in ART results in physical or psychological injury. In the event that either of us incurs such an injury, DHMC staff will assist us in gaining access to appropriate treatment, but we agree that we will remain responsible for the cost of such treatment.

We realize that in vitro fertilization is a precisely timed procedure which relies heavily upon patient participation and cooperation. Patients are required to appear for a variety of tests and procedures, and in all cases it is their responsibility to arrive at the designated location at the assigned times. We also realize that there are psychological risks of participation in an ART cycle and we have been counseled accordingly.

If we are using embryo freezing, we understand that it is our responsibility:

(a) to keep DHMC ART Program staff informed of our current address(es) by sending written notification of address changes to the ART Program so that any notice sent by DHMC ART Program staff or the DHMC leadership regarding our frozen embryos will reach us promptly; and

(b) to respond within 30 days to any such notice;

(c) to pay all storage fees and to make prompt arrangements to pay all other DHMC bills in a timely manner; and

Initials: Patient __________________ Partner (if applicable) __________________ 17

Health Information Services Approval: 4/11/2012 Version Date: 4/11/2012
(d) to immediately inform DHMC ART Program staff of any and all changes in our marital status.

We understand that there are special risks to cycles using donated gametes as described above in section on donated gametes.

We/I agree to assume full responsibility for all costs incurred by us as a result of our participation in ART treatment at DHMC. If we are using donated eggs from a donor who is donating eggs specifically for our use, we agree to assume full responsibility for all costs incurred by the egg donor as a result of the donation of her eggs, unless we have entered an express, written agreement with the egg donor that otherwise allocates such costs as between the egg donor and us.

We/I understand that the costs associated with IVF and Embryo Freezing are billed according to services rendered and will vary according to the circumstances. For instance, treatment cannot continue if the woman's or donor's eggs are not suitable for harvest or if fertilization does not occur. Cost is also influenced by the type of anesthesia chosen for the egg harvest procedure. We/I have discussed the factors that may affect cost with a representative of Patient Financial Relations who represents Mary Hitchcock Memorial Hospital and the Dartmouth-Hitchcock Clinic. We/I understand that most health insurance plans will not cover these costs, and we/I assume responsibility for determining what portions of treatment, if any, our insurance will cover and for arranging payment.

We/I hereby release the Dartmouth-Hitchcock Medical Center, its component institutions, and internal committees, and their successors (including, without limitation, the Dartmouth-Hitchcock Clinic, the Mary Hitchcock Memorial Hospital, the Dartmouth Medical School, the Mary Hitchcock Memorial Hospital Ethics Advisory Committee, and the DHMC ART Program) and all physicians, staff personnel and other individuals connected in any way with the ART Program from all common-law, statutory or other liability of any kind for injuries of any kind -- whether physical, mental, emotional, monetary or other -- suffered by either of us, by any child born to us as a result of the IVF and/or Embryo Freezing Procedures, or by any pronuclear embryo, embryo or fetus conceived as a result of either procedure, except that no individual or institution shall be released from liability for injuries that occur as a result of gross negligence or intentional misconduct by that individual or institution. We/I also specifically (but without limitation) release all such individuals and institutions from any liability whatsoever for our failure to achieve pregnancy through the use of the IVF and/or Embryo Freezing procedures, for the cremation of any eggs that are not fertilized for any reason, for allowing to die those embryos (whether or not fertilized and dividing) which are not transferred back to the woman for any reason and, if we/I have requested embryo freezing, for thawing our frozen embryos and allowing them to die for any reason, whether with or without our consent. We/I acknowledge that the IVF procedure has inherent risks which we/I are assuming. We/I are asking to participate in the ART Program by choice, not because the treatment is, in any sense, medically required for either of us and not because we/I have been urged to participate by any physician or other individual connected with the Dartmouth-Hitchcock Medical Center.

We/I agree to indemnify (reimburse for losses and expenses) the Dartmouth-Hitchcock Medical Center, its component institutions, the DHMC ART Program, the Mary Hitchcock Memorial Hospital Ethics Advisory Committee, and any physicians, staff personnel, or other individuals connected with the ART Program in connection with any liability, including costs and reasonable attorneys' fees, incurred:

(a) as a result of any breach by us of paragraphs in Section J hereof; or

(b) as a result of any misrepresentation by either of us to DHMC staff regarding our age, marital status, or other relevant facts; or

(c) in connection with any claim by or on behalf of any pronuclear embryos, embryos, fetuses, or children conceived or born as a result of the IVF and/or the Embryo Freezing procedure, except
any claim based upon gross negligence or intentional misconduct in connection with the in vitro fertilization or embryo freezing process.

We/I agree that we/I each accept all of the legal rights and responsibilities of parenthood with respect to any child born to the female participant whose signature appears below as a result of our participation in the ART Program, including responsibility for child support. We/I both expressly agree that the male participant whose name and signature appear below shall be the legal father of any child born to the female participant as a result of our participation in the ART Program and that the female participant shall be the legal mother of that child.

[Female participants only] I hereby certify that (place initials next to applicable statements):

_____ I am 21 years of age or older.

_____ I am married to the man who, along with me, has signed this document.

_____ I am unmarried.

[Male participants only] I hereby certify that (place initials next to applicable statements):

_____ I am 21 years of age or older.

_____ I am married to the woman who, along with me, has signed this document.

_____ I am unmarried.

We/I hereby certify that we/I have read this release and the accompanying information. Our questions regarding the rights that we/I have retained and the rights that we/I have waived have been answered to our satisfaction. If we/I have further questions, we/I understand that we/I may discuss them with DHMC staff.

We/I understand that this consent form is good for procedures done for a FULL YEAR from the date of our signatures. We/I further understand that it is OUR RESPONSIBILITY to NOTIFY the DHMC ART Program of any changes in our marital status that could lead us to desire that this consent no longer be in effect.

_______________________________________________
Signature of Patient

_______________________________________________
Signature of Spouse/Partner

_______________________________________________
Witness

I have reviewed the risks and benefits of the IVF procedure with the participants.

_______________________________________________
Signature of Physician             Date             Time             (All Signed)
**TRANSLATOR**

If the translator is necessary and physically present, please request a signature below:

<table>
<thead>
<tr>
<th>Signature of person translating information for patient</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
</table>

If translation is done using a commercially available language line, identify the name of the translator and the commercial service.

<table>
<thead>
<tr>
<th>Name of individual translating information for patient</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
</table>

Name of commercial services vendor